Alamar Biosciences reports director Ian Ratcliffe's death

Alamar Biosciences, Inc. reported that board member Ian Ratcliffe, an independent director since February 2024, passed away on July 5, 2026.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. reported that board member Ian Ratcliffe, an independent director since February 2024, passed away on July 5, 2026. The company expressed condolences and acknowledged his dedication and service.

Following his passing, the board reduced the authorized number of directors constituting the full board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the board.

Positive

• None.

Negative

• Independent director Ian Ratcliffe, who served on the board since February 2024, passed away on July 5, 2026, resulting in the loss of an experienced board member and prompting changes in board composition.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Director passing date: July 5, 2026 Board size after change: 5 directors Start of board service: February 2024

3 metrics

Director passing date July 5, 2026 Date on which independent director Ian Ratcliffe passed away

Board size after change 5 directors Authorized number of directors constituting the full board after adjustment

Start of board service February 2024 Month and year Ian Ratcliffe began serving as an independent director

Key Terms

independent director, Audit Committee, Emerging growth company

3 terms

independent director regulatory

"Mr. Ratcliffe served as an independent director on the Board since February 2024."

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Audit Committee regulatory

"and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board."

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

Emerging growth company regulatory

"Emerging growth company Alamar Biosciences, Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alamar Biosciences (ALMR) announce regarding director Ian Ratcliffe?

Alamar Biosciences announced that independent director Ian Ratcliffe passed away on July 5, 2026. He had served on the board since February 2024, and the company expressed gratitude for his dedication and extended condolences to his family.

How did Alamar Biosciences (ALMR) change its board size after Ian Ratcliffe’s passing?

After Ian Ratcliffe’s passing, Alamar Biosciences’ board decreased the number of authorized directors constituting the full board to five. This adjustment reflects the updated board structure following the loss of one of its independent directors.

Who was appointed to the Audit Committee at Alamar Biosciences (ALMR)?

Alamar Biosciences appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the board. This appointment followed the passing of independent director Ian Ratcliffe and forms part of the company’s updated board and committee composition.

How long did Ian Ratcliffe serve on the Alamar Biosciences (ALMR) board?

Ian Ratcliffe served as an independent director on the Alamar Biosciences board from February 2024 until his passing on July 5, 2026. The company highlighted his dedication and service during this period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:04 PM EDT Learn about SEC filing dates

false 0002104204 0002104204 2026-07-15 2026-07-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2026

Alamar Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-43235		36-4899036
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47071 Bayside Parkway

Fremont, CA 94538

(Address of principal executive offices)

Registrant’s telephone number, including area code: (510) 626-9888

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ALMR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026. The Company’s management and Board extend their sincerest condolences to Mr. Ratcliffe’s family. Mr. Ratcliffe served as an independent director on the Board since February 2024. The Company is extremely grateful for Mr. Ratcliffe’s dedication and service to the Company.

Following Mr. Ratcliffe’s passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Alamar Biosciences, Inc.
By:		/s/ Justin McAnear
		Justin McAnear
		Chief Financial Officer

Dated: July 15, 2026

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB